A ALIMENTARY TRACT AND METABOLISM
|
|
B BLOOD AND BLOOD FORMING ORGANS
|
|
C CARDIOVASCULAR SYSTEM
|
|
D DERMATOLOGICALS
|
|
G GENITO URINARY SYSTEM AND SEX HORMONES
|
|
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
|
|
J ANTIINFECTIVES FOR SYSTEMIC USE
|
|
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
|
L01 ANTINEOPLASTIC AGENTS
|
L02 ENDOCRINE THERAPY
|
L03 IMMUNOSTIMULANTS
|
L04 IMMUNOSUPPRESSANTS
|
L04A IMMUNOSUPPRESSANTS
|
L04AA Selective immunosuppressants
|
L04AA02 Muromonab-CD3
|
L04AA03 Antilymphocyte immunoglobulin (horse)
|
L04AA04 Antithymocyte immunoglobulin (rabbit)
|
L04AA06 Mycophenolic acid [DG:DG00739]
|
L04AA10 Sirolimus
|
L04AA13 Leflunomide
|
L04AA15 Alefacept
|
L04AA18 Everolimus
|
L04AA19 Gusperimus [DG:DG00740]
|
L04AA21 Efalizumab
|
L04AA22 Abetimus
|
L04AA23 Natalizumab
|
L04AA24 Abatacept
|
L04AA25 Eculizumab
|
L04AA26 Belimumab
|
L04AA27 Fingolimod [DG:DG00741]
|
L04AA28 Belatacept
|
L04AA29 Tofacitinib [DG:DG00742]
|
D09970 Tofacitinib (USAN)
D09783 Tofacitinib citrate (JAN/USAN) <JP/US>
|
L04AA31 Teriflunomide
|
L04AA32 Apremilast
|
L04AA33 Vedolizumab
|
L04AA34 Alemtuzumab
|
L04AA35 Begelomab
|
L04AA36 Ocrelizumab
|
L04AA37 Baricitinib
|
L04AA38 Ozanimod [DG:DG02827]
|
L04AA39 Emapalumab
|
L04AA40 Cladribine
|
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
|
L04AC Interleukin inhibitors
|
L04AD Calcineurin inhibitors
|
L04AX Other immunosuppressants
|
|
M MUSCULO-SKELETAL SYSTEM
|
|
N NERVOUS SYSTEM
|
|
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
|
|
R RESPIRATORY SYSTEM
|
|
S SENSORY ORGANS
|
|
V VARIOUS
|